Inno-206
Sickle Beta Plus Thalassemia
M.D. Anderson Cancer CenterEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Sickle Beta Plus Thalassemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TACROLIMUS M.D. Anderson Cancer Center | Early Phase 1 | C |
Monomethyl Fumarate M.D. Anderson Cancer Center | Early Phase 1 | C |
Cyclophosphamide M.D. Anderson Cancer Center | Early Phase 1 | C |
Busulphan M.D. Anderson Cancer Center | Early Phase 1 | C |
Fludarabine M.D. Anderson Cancer Center | Early Phase 1 | C |
View all 11 →
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →